Lowering the TG/HDL-C ratio can prevent type 2 diabetes and type 2 diabetes.

Published Date: 17 Mar 2023

Iran: According to a study published in Diabetology and Metabolic Syndrome, triglycerides are elevated in normoglycemic patients.

Read Full News

Latest News

Levothyroxine Discontinuation Safe for Many Older Adults

About 1 in 4 overall and two thirds of those taking doses of 50 µg/d or lower were able to come off the treatment while maintaining adequate thyroid function for 1 year.

Nuanced Sexual and Pelvic Floor Effects of GLP-1s on Women

Emerging research and anecdotal reports suggest that the weight-loss drugs may cause vulvar and urogenital changes.

Patients With Acromegaly Have Higher Risk for Cancer

Patients with acromegaly show a significantly higher risk for cancer than matched control individuals from the general population, with the risk being evident even 5 years before diagnosis.

APHRODITE Model May Improve Care in Male Infertility

A new classification framework introduces structured phenotyping to guide hormonal therapy in male infertility, addressing long-standing reliance on empirical treatment approaches.

Novo Nordisk Launches Higher-dose Wegovy in the United States

Novo Nordisk said on Tuesday that it has made ⁠a higher-dose version of its blockbuster weight-loss drug Wegovy ⁠available across the United States.

Weight Loss After Tirzepatide Varies by Prior Weight Change

Tirzepatide produced notable weight loss in real-world settings, but patients with prior weight loss experienced smaller additional reductions than those without.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Latest News

About 1 in 4 overall and two thirds of those taking doses of 50 µg/d or lower were able to come off the treatment while maintaining adequate thyroid function for 1 year.

Emerging research and anecdotal reports suggest that the weight-loss drugs may cause vulvar and urogenital changes.

Patients with acromegaly show a significantly higher risk for cancer than matched control individuals from the general population, with the risk being evident even 5 years before diagnosis.

A new classification framework introduces structured phenotyping to guide hormonal therapy in male infertility, addressing long-standing reliance on empirical treatment approaches.

Novo Nordisk said on Tuesday that it has made ⁠a higher-dose version of its blockbuster weight-loss drug Wegovy ⁠available across the United States.

Tirzepatide produced notable weight loss in real-world settings, but patients with prior weight loss experienced smaller additional reductions than those without.

News All Time

Sugar Tax Debate Intensifies as Health Evidence Builds

Evidence suggests that sugar taxes may influence obesity patterns among younger populations.

Airline Websites Vary on Info for Passengers With Obesity

Across 50 leading airlines globally, all offer some content for passengers with obesity, but the specifics vary widely.

Gene Therapy to Be Studied for Treating Type 1 Diabetes

A phase 1/2 trial of a novel viral vector gene therapy in adults with type 1 diabetes is scheduled to begin this year.

Viridian Eye Disease Drug Disappoints on Efficacy Despite Trial Success

Viridian Therapeutics' experimental treatment for thyroid eye ⁠disease lagged rivals in efficacy in a late-stage...

Beyond Diabetes Control: Tirzepatide Boosts Quality of Life

Switching to tirzepatide yields greater quality-of-life benefits than increasing the dulaglutide dose in patients with type 2 diabetes.

BMI Misclassifies Many Adults With Obesity

Researchers using the gold-standard DEXA to measure body fat percentage showed that BMI misclassified a notable proportion of adults, placing many in incorrect weight categories.

Novo Nordisk Cuts Ozempic, Wegovy Prices in India Again to Fight Cheaper Generics

Novo Nordisk has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and ⁠48% in India, to fend off competition from...

Tirzepatide Boosts Metabolic Health in Partial Lipodystrophy

Tirzepatide significantly improves metabolic health and reduces insulin dependence in patients with partial lipodystrophy.

EMA Clears New First-Line Options for Advanced Cancers

European regulators have backed RET inhibitor and PD-1 regimens, expanding first line options in advanced lung, thyroid, and esophageal cancers.

NICE Introduces Endometriosis Fertility Pathway

An updated NICE guideline sets out a dedicated pathway for endometriosis within wider fertility guidance.

Weight Loss May Cut Cancer Risk in Adults With Obesity

Nonsurgical weight loss is associated with reduced incident risks for both obesity-related and other cancers in adults with obesity.

Medtronic Gets US FDA Nod to Use Surgical System in Cranial, ENT Surgeries

Medtronic said on Friday the U.S. Food and Drug Administration has cleared its surgical system ⁠for cranial and ear, nose and throat procedures, expanding the platform...

EU Reaffirms Rejection of Rare Sleep Disorder Drug

The sleep drug failed to gain approval for nighttime disruptions in children with a rare genetic disorder affecting circadian rhythm patterns.

Experts Question Evidence for New Testosterone Advice

New federal dietary guidance includes advice on boosting testosterone levels, which clinicians say is only partially rooted in evidence.

Once- or Twice-Yearly Injection for Weight Loss?

Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.

Do ESAs for Anemia Raise Cancer Risk in Dialysis Patients?

High doses of erythropoiesis-stimulating agents were associated with an increased risk for cancer in patients on dialysis, but the real risk attributed to these medications remains unclear.

Recommended News For You

In schizophrenia, sexual dysfunction is frequent.

Some low-grade prostate cancers carry higher risks than biopsy suggests

New protein target discovered for childhood medulloblastomas

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

'Personalized' Approach to RT for Bladder Cancer Promising but Challenging

Adopted cancer cells and the effects of their presence.

Fitness levels for the heart and lungs are linked to a lower mortality from cancer in men.

Recommended Articles For You

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients 

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects  

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

2.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

3.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

4.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

5.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

1.

The Capmist DM: A Revolutionary Way to Combat Dry Mouth

2.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

3.

How Prevident is Revolutionizing Oral Care

4.

The Importance of Early Detection: How Genetics Play a Role in Leucocythemia Diagnosis 

5.

Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

2.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

5.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot